Published in J Virol on September 01, 1997
Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol (1999) 4.54
DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol (2001) 2.95
The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol (2000) 2.03
Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol (1999) 1.72
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus. J Exp Med (1999) 1.67
CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol (2002) 1.66
Inhibition of simian immunodeficiency virus (SIV) replication by CD8(+) T lymphocytes from macaques immunized with live attenuated SIV. J Virol (1998) 1.59
Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J Virol (2000) 1.57
Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol (1998) 1.53
HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci U S A (2000) 1.53
The human immunodeficiency virus type 1 nef gene can to a large extent replace simian immunodeficiency virus nef in vivo. J Virol (1999) 1.26
Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. J Virol (2009) 1.24
Nef proteins from diverse groups of primate lentiviruses downmodulate CXCR4 to inhibit migration to the chemokine stromal derived factor 1. J Virol (2005) 1.20
CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120. Proc Natl Acad Sci U S A (1998) 1.15
Simian immunodeficiency virus utilizes human and sooty mangabey but not rhesus macaque STRL33 for efficient entry. J Virol (2000) 1.12
The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J Virol (2006) 1.09
Nonhuman primate models of NeuroAIDS. J Neurovirol (2008) 1.07
Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol (2000) 1.04
Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells. J Virol (2000) 1.02
An African green monkey lacking peripheral CD4 lymphocytes that retains helper T cell activity and coexists with SIVagm. Clin Exp Immunol (1999) 1.02
Morphine potentiates neuropathogenesis of SIV infection in rhesus macaques. J Neuroimmune Pharmacol (2011) 1.00
Induction of disseminated Mycobacterium avium in simian AIDS is dependent upon simian immunodeficiency virus strain and defective granuloma formation. Am J Pathol (2001) 0.95
Simian immunodeficiency virus SIVrcm, a unique CCR2-tropic virus, selectively depletes memory CD4+ T cells in pigtailed macaques through expanded coreceptor usage in vivo. J Virol (2009) 0.95
Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors. J Virol (2004) 0.91
CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses. J Virol (2000) 0.89
CD4-independent, CCR5-dependent simian immunodeficiency virus infection and chemotaxis of human cells. J Virol (2000) 0.86
Development and characterization of positively selected brain-adapted SIV. Virol J (2005) 0.84
Is an HIV vaccine possible? Braz J Infect Dis (2009) 0.83
CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques. J Med Primatol (2011) 0.82
Multiple roles for chemokines in the pathogenesis of SIV infection. Curr HIV Res (2009) 0.80
Rhesus macaque model of chronic opiate dependence and neuro-AIDS: longitudinal assessment of auditory brainstem responses and visual evoked potentials. J Neuroimmune Pharmacol (2009) 0.80
Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS. J Virol (2011) 0.79
Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)). J Virol (2001) 0.76
Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. J Transl Med (2011) 0.76
The KT Jeang Retrovirology prize 2016: Frank Kirchhoff. Retrovirology (2016) 0.75
Virion background and efficiency of virion incorporation determine susceptibility of SIV-Env-driven viral entry to inhibition by IFITM proteins. J Virol (2016) 0.75
Clearly different mechanisms of enhancement of short-lived Nef-mediated viral infectivity between SIV and HIV-1. Virol J (2014) 0.75
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science (1990) 8.07
Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science (1985) 6.02
The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1990) 5.79
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med (1996) 5.46
Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (1989) 5.12
Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol (1990) 5.01
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85
Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med (1996) 4.57
Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry (1996) 4.35
The simian immunodeficiency viruses. Annu Rev Immunol (1990) 4.32
Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol (1991) 3.46
A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol (1996) 3.26
Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol (1992) 3.16
Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol (1990) 3.07
Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol (1991) 2.84
Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol (1993) 2.70
The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol (1992) 2.49
Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol (1996) 2.49
Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS. Am J Pathol (1991) 2.38
Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol (1992) 2.30
The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. Virology (1991) 2.15
Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization. J Virol (1992) 1.94
Animal models of AIDS. FASEB J (1989) 1.82
Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS. J Virol (1993) 1.77
Identification of viral determinants of macrophage tropism for simian immunodeficiency virus SIVmac. J Virol (1991) 1.71
Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol (1990) 1.65
The "V3" domain is a determinant of simian immunodeficiency virus cell tropism. J Virol (1994) 1.40
Spontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virus. J Virol (1994) 1.39
Distinctive pattern of infection and replication of HIV1 strains in blood-derived macrophages. Virology (1992) 1.39
Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology (1995) 1.31
Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J Virol (1994) 1.24
Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20
Replication-competent chimeric lenti-oncovirus with expanded host cell tropism. J Virol (1997) 0.83
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 5.06
Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry (2001) 4.70
Manifestation of atopy is not related to patient's month of birth. Allergy (1993) 2.11
Circulatory and respiratory complications of carbon dioxide insufflation. Dig Surg (2004) 2.06
Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol (1998) 1.94
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79
Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. Eur J Immunol (1992) 1.67
Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med (1991) 1.66
Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart (2001) 1.59
Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV. J Pathol (2001) 1.58
Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol (1999) 1.57
Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther (2000) 1.52
Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J Virol (2001) 1.48
Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol (2000) 1.47
Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood (2000) 1.46
[Findings in a high-risk group following asbestos exposure. Benefit of ENT examinations in patients with long-term exposure to asbestos]. HNO (2002) 1.39
DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol (2001) 1.34
Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res (1999) 1.33
Enhanced production of LPS-induced cytokines during differentiation of human monocytes to macrophages. Role of LPS receptors. J Immunol (1993) 1.29
The role of DC-SIGN and DC-SIGNR in HIV and SIV attachment, infection, and transmission. Virology (2001) 1.29
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis (1980) 1.22
Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther (1996) 1.21
Solitary fibrous tumour of the pleura: surgical treatment. Eur J Cardiothorac Surg (2001) 1.21
Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20
Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther (2000) 1.18
[Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie (2010) 1.14
Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. J Virol (2000) 1.13
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother (2000) 1.12
SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.10
Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS (2000) 1.10
Design elements for a computerized patient record. Methods Inf Med (1999) 1.10
Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med (2000) 1.08
Multistate outbreak of Salmonella serovar Muenchen infections associated with alfalfa sprouts grown from seeds pretreated with calcium hypochlorite. J Clin Microbiol (2001) 1.08
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study. Thromb Haemost (1979) 1.08
Altered cytokine production and accessory cell function after HIV-1 infection. J Immunol (1996) 1.06
Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun (1995) 1.06
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie (2010) 1.06
Roundtable discussion: symposium: medical perspectives on passive smoking. Prev Med (1984) 1.02
Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res (2001) 1.02
Interleukin-4-mediated tumor suppression in nude mice involves interferon-gamma. Eur J Immunol (1992) 1.00
Pneumoconiosis and emphysema in construction workers: results of HRCT and lung function findings. Occup Environ Med (2011) 0.98
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol (1999) 0.97
Maternal smoking during pregnancy and lactation increases the risk for atopic eczema in the offspring. J Am Acad Dermatol (1997) 0.96
Reduced leptin levels in human narcolepsy. Neuroendocrinology (2000) 0.95
Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology (2000) 0.94
Molecular piracy of Kaposi's sarcoma associated herpesvirus. Cytokine Growth Factor Rev (2001) 0.94
[The role of 3-D imaging and computer-based postprocessing for surgery of the liver and pancreas]. Rofo (2005) 0.93
Activity of human immunodeficiency virus type 1 promoter/TAR regions and tat1 genes derived from individuals with different rates of disease progression. Virology (1997) 0.92
Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines. J Virol (1998) 0.92
A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping. Leukemia (2001) 0.91
[Health effects of particulate matter exposure: current scientific knowledge]. Pneumologie (2009) 0.91
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie (2011) 0.91
Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy. Antivir Ther (2000) 0.90
Comminuted fractures of the proximal ulna--Preliminary results with an anatomically preshaped locking compression plate (LCP) system. Injury (2010) 0.88
Ghrelin and eating disturbances in psychiatric disorders. Neuropsychobiology (2008) 0.88
A user-oriented protocol for integrating heterogeneous communication systems of medical facilities using ports. Methods Inf Med (1989) 0.87
Levels of 8-hydroxy-2'-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany. Mutat Res (2000) 0.87
The Baumann procedure to correct equinus gait in children with diplegic cerebral palsy: long-term results. J Bone Joint Surg Br (2012) 0.86
[Automatic production of a doctors letter in obstetrics, based of computerized data (author's transl)]. Z Geburtshilfe Perinatol (1973) 0.86
Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines. Vaccine (2009) 0.86
Perceived risk of bovine spongiform encephalopathy and dietary behavior. J Health Psychol (2003) 0.86
Complexity of biomedical data models in cardiology: the Intranet-based AF registry. Comput Methods Programs Biomed (2002) 0.86
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia. Acta Psychiatr Scand (2000) 0.85
Proteomics in neurodegeneration--disease driven approaches. J Neural Transm (Vienna) (2006) 0.85
Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine (2000) 0.84
[EDV complete documentation in obstetrics with the aid of "proof-marks". A step in the framework of a clinical information system (author's transl)]. Z Geburtshilfe Perinatol (1973) 0.84
Effects of sleep on endotoxin-induced host responses in healthy men. Psychosom Med (2001) 0.84
ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+. Oncogene (2000) 0.84
Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology (2002) 0.84
A method for the quantification of biomarkers of exposure to acrylonitrile and 1,3-butadiene in human urine by column-switching liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2008) 0.84
Fabrication of silicon nanowire arrays by near-field laser ablation and metal-assisted chemical etching. Nanotechnology (2016) 0.84
Analysis of quality and feasibility of an objective structured clinical examination (OSCE) in preclinical dental education. Eur J Dent Educ (2011) 0.84
Activators of protein kinase C enhance accumulation of interferon-beta mRNA in murine cell lines. J Interferon Res (1989) 0.83
Generation of replication-defective helper-free vectors based on simian immunodeficiency virus. Virology (2001) 0.83
Replication-competent chimeric lenti-oncovirus with expanded host cell tropism. J Virol (1997) 0.83
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol (2010) 0.83
A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. Pharmacopsychiatry (2000) 0.83
How Ebola virus counters the interferon system. Zoonoses Public Health (2012) 0.83
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry (1997) 0.82
Experimental immunomodulation, sleep, and sleepiness in humans. Ann N Y Acad Sci (2000) 0.82
Selection of reference films based on reliability assessment of a classification of high-resolution computed tomography for pneumoconioses. Int Arch Occup Environ Health (2006) 0.82
[Testing of orally administered spasmolytics demonstrated by the effect of hyoscine-N-butylbromide on gastric motility]. Arzneimittelforschung (1968) 0.82
Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder. J Sleep Res (1999) 0.82
[Medical informatics]. Neue Munch Beitr Gesch Med Naturwiss Medizinhist Reihe (1978) 0.82
Progressive changes in CD45RB phenotype and lymphokine production by murine CD4+ T cells after alloantigen exposure. Immunology (1992) 0.82
In vivo degradation performance of micro-arc-oxidized magnesium implants: a micro-CT study in rats. Acta Biomater (2012) 0.81
Haemostasiological parameters as risk factor for new arterial occlusions in diabetics. Klin Wochenschr (1986) 0.81
The German competence network 'Acute and chronic leukemias'. Leukemia (2004) 0.81
Association between 8-hydroxy-2'-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinical data, occupational and non-occupational confounding factors, and cancer. Mutat Res (2000) 0.81
Dacron vs. polytetrafluoroethylene grafts for femoropopliteal bypass: a prospective randomised multicentre trial. Eur J Vasc Endovasc Surg (2001) 0.81
Biomonitoring of nickel and chromium in human pulmonary tissue. Int Arch Occup Environ Health (1993) 0.81
Soluble thrombomodulin--a marker of reperfusion injury after orthotopic liver transplantation. Transplantation (1995) 0.81